非霍奇金淋巴瘤患者化疗后肝功能损害与乙肝病毒标志物的相关性分析  

Clinical Analysis of the Correlation between Liver Damage and HBV Markers after Chemotherapy in Patients with Non-Hodgkin's Lymphoma

作　　者：陈彦帆[1] 韦燕[1] 龚建忠[1] 赵善琳[1] 张芸[1] 宁春玉[1] 

机构地区：[1]广西贵港市人民医院,537100

出　　处：《实用癌症杂志》2010年第6期646-647,651,共3页The Practical Journal of Cancer

摘　　要：目的探讨非霍奇金淋巴瘤患者化疗期间肝功能损害与乙肝病毒(HBV)标志物阳性表达的相关性。方法 65例非霍奇金淋巴瘤患者,其中乙肝病毒阳性32例,均采用EPOCH方案化疗。结果乙肝病毒阳性非霍奇金淋巴瘤患者,化疗期间肝功能损害较乙肝病毒阴性者明显,肝功能损害总体发生率为46.9%VS18.2%,P值=0.013,差异有统计学意义。合并乙肝大三阳或乙肝小三阳者Ⅲ～Ⅳ度肝功能损害发生率较高,达33.3%,无化疗相关死亡病例。结论乙肝病毒阳性非霍奇金淋巴瘤患者化疗后肝功能损害发生率较乙肝病毒阴性者高。乙肝大三阳、乙肝小三阳患者尤其明显。建议非霍奇金淋巴瘤患者化疗前进行乙肝两对半检查,并监测肝功能。Objective To investigate the changes of liver function in patients with Non-Hodgkin＇s lymphoma（NHL） after chemotherapy,and to assess the correlation between the liver damage and Hepatitis B virus（HBV） markers.Methods Of the 65 NHL patients,32 were HBV positive.ALL patients were treated with CHOEP.Results Significantly more liver damage was seen in patients with positive markers of hepatitis B than in those with negative markers after chemotherapy（46.9% VS 18.2%,P = 0.013）.Grade Ⅲ-Ⅳ liver damage was 33.3% in patients with positive HBsAg,HBeAg and HBcAb,or positive HBsAg,HBeAb and HBcAb.Conclusion Liver damage rate in NHL patients with positive markers of hepatitis B is significantly higher than in those with negative markers,especially in patients with positive HBsAg,HBeAg and HBcAb,or positive HBsAg,HBeAb and HBcAb after chemotherapy.It might be helpful to detect the blood markers of hepatitis B before chemotherapy.

关 键 词：非霍奇金淋巴瘤 肝功能损害 乙肝病毒阳性 

分 类 号：R733.4[医药卫生—肿瘤]